Literature DB >> 8261659

Effects of verapamil and diltiazem on dopamine release in the central nervous system of spontaneously hypertensive rats.

K Tsuda1, S Tsuda, M Goldstein, Y Masuyama.   

Abstract

1. The purpose of the present study was to investigate the effects of Ca(2+)-antagonists (verapamil and diltiazem) on dopamine release in the central nervous system in hypertension. 2. Striatal slices obtained from spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats were prelabelled with [3H]-dopamine, and superfused with Krebs-Ringer solution in vitro. The slices were stimulated electrically at a frequency of 1 Hz. 3. Stimulation-evoked release of [3H]-dopamine from striatal slices was significantly decreased in SHR compared with WKY rats. 4. Exposure of slices to verapamil and diltiazem significantly increased the stimulation-evoked [3H]-dopamine release. The facilitatory effects of the Ca(2+)-antagonists on dopamine release were significantly greater in SHR than in WKY rats. 5. Because central nervous system dopaminergic mechanisms appear to be depressor, the results suggest that the pronounced effects of verapamil and diltiazem on dopamine release in SHR might be involved in the central hypotensive mechanisms of the Ca(2+)-antagonists.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8261659     DOI: 10.1111/j.1440-1681.1993.tb01646.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  2 in total

1.  Verapamil attenuates scopolamine induced cognitive deficits by averting oxidative stress and mitochondrial injury - A potential therapeutic agent for Alzheimer's Disease.

Authors:  Saravanaraman Ponne; Chinnadurai Raj Kumar; Rathanam Boopathy
Journal:  Metab Brain Dis       Date:  2019-11-05       Impact factor: 3.584

2.  Renin-Angiotensin system and sympathetic neurotransmitter release in the central nervous system of hypertension.

Authors:  Kazushi Tsuda
Journal:  Int J Hypertens       Date:  2012-11-21       Impact factor: 2.420

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.